Technology | Implantable Cardiac Monitor (ICM) | March 15, 2017

Medtronic Receives FDA Clearance for Reveal LINQ Insertable Cardiac Monitor With TruRhythm Detection

Device delivers improved accuracy and streamlined data for clinicians

Medtronic, Reveal LINQ ICM, insertable cardiac monitor, FDA clearance, TruRhythm Detection

March 15, 2017 — Medtronic plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Reveal LINQ Insertable Cardiac Monitor (ICM) with TruRhythm Detection. The advanced cardiac monitor offers improved accuracy to better identify abnormal heartbeats.

Medtronic said Reveal LINQ ICM with TruRhythm Detection offers exclusive algorithms that result in a 95 percent reduction in false bradycardia (slow heartbeat) episodes and a 47 percent reduction in false pause (brief absence of cardiac activity) episodes when compared with its predecessor, the Reveal LINQ ICM. The device also features a self-learning atrial fibrillation algorithm, which learns and adapts to a patient’s heart rhythm over time. AF episodes, which are most likely to trigger false positives with ICMs, experienced a 49 percent reduction in false detections with the Reveal LINQ ICM with TruRhythm Detection when compared to the Reveal LINQ ICM.[i]

“ICMs help physicians find answers for patients at risk for cardiac arrhythmias to better manage a range of patient populations," said James Allred, M.D., electrophysiologist at Cone Health Medical Group Heartcare in Greensboro, N.C. “The enhancements with the Reveal LINQ ICM with TruRhythm Detection make it smarter by streamlining device data review so physicians can make decisions more accurately and quickly for patients.”

Reveal LINQ ICM with TruRhythm Detection, which allows physicians to continuously and wirelessly monitor a patient’s heartbeat for up to three years, is approximately one-third the size of an AAA battery (~1 cc). It is placed just beneath the skin through a small incision of less than 1 cm in the upper left side of the chest, using a minimally invasive procedure, and its presence is often nearly undetectable to the naked eye once the incision has healed. The device communicates wirelessly with a patient bedside monitor that uploads device data to the Medtronic CareLink network; it is MR-Conditional, allowing patients to undergo magnetic resonance imaging (MRI), if needed.

For more information: www.medtronic.com

Related Content

Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve ar
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
Sponsored Content | Videos | Business| June 06, 2017
Andrea Natale, M.D., FACC, FHRS, FESC, executive medical director, Texas Cardiac Arryhthmia Institute at St.
Biosense Webster's multi-electrode RF ablation balloon

The most popular technology in May was the first data released on Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | June 01, 2017 | Dave Fornell
June 1, 2017 — Here is the list of the most popular pieces of content on the Diagnostic and Interventional Cardiology
Northwell Health Partners With Peerbridge Health on Remote Patient Monitoring
News | Wearable Sensors| June 01, 2017
Northwell Health recently announced a new partnership agreement with Peerbridge Health Inc., to explore the future of...
Infab Introduces Revolution Lead Aprons
Technology | Radiation Dose Management| June 01, 2017
June 1, 2017 — Infab Corp.
Sponsored Content | Videos | Implantable Cardioverter Defibrillators (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
Overlay Init